Loading...
•
Sep 30, 2022
Xencor Q3 2022 Earnings Report
Xencor reported financial results, highlighted XmAb564 clinical data, and reviewed recent business activities.
Key Takeaways
Xencor reported Q3 2022 financial results, with total revenue of $27.3 million and a net loss of $32.8 million, or $(0.55) per share. The company's cash, cash equivalents, receivables, and marketable debt securities totaled $654.6 million as of September 30, 2022. Xencor also announced initial results from its Phase 1a study of XmAb564, which showed promising tolerability and T-cell expansion.
Xencor's XmAb technologies enable addressing challenging areas of biology and portfolio growth.
XmAb564 showed encouraging data with selective T-cell increases and tolerability.
New data from vudalimab and plamotamab clinical programs will be presented.
Xencor is committed to development plans for bispecific antibodies and advancing potency-reduced cytokines.
Xencor
Xencor
Forward Guidance
Xencor expects to have cash to fund research and development programs and operations through the end of 2025 and expects to end 2022 with between $575 million and $600 million in cash, cash equivalents, receivables and marketable debt securities.